Ischemic limb tissue

Ischemic limb tissue refers to a pathological state characterized by inadequate blood supply to the extremities, most commonly caused by peripheral artery disease (PAD) (StatPearls, 2023). This condition leads to a mismatch between oxygen supply and demand, resulting in cellular hypoxia, metabolic acidosis, and potential tissue death (NIH, 2022). While not a single molecular target, ischemic tissue is the site of action for various therapies, including vasodilators like Cilostazol and pro-angiogenic gene therapies (PubMed, 2021). The biological response to ischemia involves the activation of hypoxia-inducible factor 1-alpha (HIF-1α), which coordinates the expression of genes involved in angiogenesis and anaerobic metabolism (UniProt, 2024). Therapeutic interventions aim to prevent the progression to critical limb ischemia (CLI), which is associated with high rates of amputation and mortality (Journal of Vascular Surgery, 2020). From a drug development perspective, the tissue environment is characterized by low pH and high oxidative stress, which can influence the stability and delivery of therapeutic agents (Nature Reviews Drug Discovery, 2019).

Other names

Hypoxic limb tissueIschemic skeletal musclePeripheral ischemic tissue

Therapeutic strategies focus on vasodilation, inhibition of platelet aggregation, and stimulation of therapeutic angiogenesis to restore perfusion (StatPearls, 2023).